Michael A. Metzger - 06 Oct 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger
Issuer symbol
SNDX
Transactions as of
06 Oct 2022
Net transactions value
-$268,162
Form type
4
Filing time
07 Oct 2022, 16:05:10 UTC
Previous filing
04 Oct 2022
Next filing
10 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $142,346 +16,231 +92% $8.77 33,890 06 Oct 2022 Direct
transaction SNDX Common Stock Sale $410,508 -16,231 -48% $25.29 17,659 06 Oct 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -16,231 -100% $0.000000* 0 06 Oct 2022 Common Stock 16,231 $8.77 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 674,528 options to purchase shares of common stock that are vested and immediately exercisable and a total of 485,001 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $25.1500 to $25.4350.
F3 This option is fully vested.